HeimATHA • NASDAQ
add
Athira Pharma Inc
Við síðustu lokun
0,56 $
Dagbil
0,50 $ - 0,55 $
Árabil
0,41 $ - 4,30 $
Markaðsvirði
20,02 m. USD
Meðalmagn
245,82 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | — | — |
Rekstrarkostnaður | 25,49 m. | -27,25% |
Nettótekjur | -28,74 m. | 12,83% |
Hagnaðarhlutfall | — | — |
Hagnaður á hvern hlut | — | — |
EBITDA | -25,25 m. | 27,44% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 68,86 m. | -60,19% |
Heildareignir | 86,25 m. | -53,30% |
Heildarskuldir | 28,66 m. | -4,25% |
Eigið fé alls | 57,58 m. | — |
Útistandandi hlutabréf | 38,67 m. | — |
Eiginfjárgengi | 0,37 | — |
Arðsemi eigna | -64,54% | — |
Ávöxtun eigin fjár | -88,74% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -28,74 m. | 12,83% |
Handbært fé frá rekstri | -23,02 m. | 4,01% |
Reiðufé frá fjárfestingum | 18,04 m. | -12,81% |
Reiðufé frá fjármögnun | 12,00 þ. | — |
Breyting á handbæru fé | -4,97 m. | -50,94% |
Frjálst peningaflæði | -10,13 m. | 13,86% |
Um
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Stofnsett
2011
Höfuðstöðvar
Vefsvæði
Starfsfólk
66
